Vascular complications

Diabetic kidney disease

Nephropathy

  • Diabetic nephropathy and end-stage renal failure have been a major cause of mortality amongst young adults with type 1 diabetes
  • In recent decades a decrease in clinical nephropathy in some countries probably reflects improvements in diabetes management and glycemic control
  • Increasing and persistently elevated urinary albumin excretion may predict later diabetic nephropathy
  • Elevated blood pressure is an associated feature of diabetic kidney disease

Microalbuminuria

  • The 95th centile for albumin excretion in non-diabetic children is 7.2–7.6 µg/min
  • Persistent microalbuminuria is defined in a minimum of two out of three consecutive urine specimens
    Albumin excretion rate (AER) 20–200 µg/min in timed overnight urine collections
    or
    AER 30–300 mg/24 h in 24-h urine collections
  • Alternative definitions
    Albumin/creatinine ratio (ACR) 2.5–25 mg/mmol (spot urine) (Europe)
    [3.5–25 mg/mmol has been proposed in females because of lower creatinine excretion]
    ACR 30–300 mg/g (spot urine) (North America)
    Albumin concentration 30–300 mg/l (early morning urine)

Other causes of microalbuminuria need to be excluded, e.g. glomerulonephritis, urinary tract infection, intercurrent infections, menstrual bleeding, vaginal discharge, orthostatic proteinuria and strenuous exercise

Microalbuminuria screening

  • Screening may be performed by early morning urine albumin concentration or spot urine ACR or by timed urine collection
  • Abnormal screening values should be confirmed by repeated sampling to demonstrate persistent microalbuminuria

Recommendation

Age of microalbumin screening
  • Prepubertal onset of diabetes: 5 years after onset or at age 11 years, or at puberty (whichever is earlier), and annually thereafter
  • Pubertal onset of diabetes: 2 years after onset, and annually thereafter

Microalbuminuria monitoring

  • Abnormal screening tests should be repeated, as pediatric studies have shown that apparently ‘persistent’ microalbuminuria may disappear
  • Urinary albumin tests should be accompanied by measurements of blood pressure at least annually
  • Blood pressure values should be compared with age-appropriate centile charts. Confirmation of hypertension may be assisted by 24-h ambulatory blood pressure measurements
  • When persistent microalbuminuria is confirmed, screening for retinopathy, neuropathy and lipid abnormalities is also recommended

Prevention and intervention

  • Improve BG control
  • Strongly discourage smoking
  • Encourage healthy exercise
  • Discourage excessive nutritional protein intake (recommended maximum of 1.0–1.2 g/kg body weight per day)
  • Intervention for hypertension: no clear consensus but blood pressure should probably be maintained at less than the 95th centile for age and maturity

  • Persistent and progressive albuminuria has been found to be improved by the use of ACE inhibitors. Progression to overt nephropathy may be delayed but their place in protecting long-term renal function in young people has not yet been established. There is early evidence that even without hypertension, ACE inhibitors should be considered when persistent microalbuminuria has been confirmed
  • The introduction of ACE inhibitors must be combined with monitoring of renal function. ACE inhibitors are not licenced for use in pregnancy
 
Microalbuminuria

 
 
Consensus Guidelines 2000
Click here for 'Index'
  
  
  
  
IDF Type 1 Guidelines
IDF Type 2 Guidelines